No Sex-Based Differences Found in Treatment Timing in gMG
A single-center cohort study found no differences between males and females in the odds of starting or time to treatment in generalized myasthenia gravis (gMG), but investigators want to continue to probe more deeply into why women are more severely affected by the disease.
CPAP Treatment Can Significantly Reduce Hypertensive Adverse Outcomes in Pregnancy
When women with obstructive sleep apnea (OSA) carrying high-risk pregnancies collaborate with their health care providers to find the best individualized continuous positive airway pressure (CPAP) treatment, their risks of gestational hypertension and preeclampsia may drop appreciably
In LBCL, Barriers to CAR T Remain: SDOH and More
The social determinants of health (SDOH) that need to be tackled most urgently when it comes to which patients with large B-cell lymphoma (LBCL) do and do not receive chimeric antigen receptor T-cell therapy (CAR T) are age, sex, income, and race/ethnicity.
Proteomics Promise: Not Yet Realized in Early Prediction of HDP
Investigators hoped to use large-scale proteomics to help predict hypertensive disorders of pregnancy (HDP), using blood proteins obtained from individuals in their first trimester of pregnancy—but success has been elusive.
AAV Therapy: A Successful 1-Patient SPG50 Gene Therapy Trial
An adeno-associated virus (AAV) gene therapy for hereditary spastic paraplegia type 50 (SPG50)—funded by a young patient’s family—gives hope not only to a 4-year-old, but to researchers working on similar projects for other rare diseases.
ViPOR: Novel Targeted Therapy Combination Shows Potential in Relapsed DLBCL
The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes.
Thymectomy in Children With Myasthenia Gravis: An Option to Consider
Results of a recent database analysis reveal that patients with juvenile myasthenia gravis—particularly prepubescent girls—might benefit from early thymectomy to cut production of autoreactive AChR B cells. Usually, though, it’s not done.
Polatuzumab Vedotin: Review Spotlights Its Use, Promise in DLBCL
With its recent approvals around the world to treat newly diagnosed and relapsed/refractory diffuse large B-cell lymphoma (DLBCL), the antibody-drug conjugate polatuzumab vedotin is changing regimens for current and future patients, with manageable adverse effects.
Patients With T1D and HCPs Talk Social Media and Self-Management
Synthesizing 11 qualitative studies, authors present a nuanced picture of how patients with type 1 diabetes (T1D), and the health care professionals (HCPs) who treat them, feel about using social media platforms as a self-management tool—and where improvements can be made.
Inotuzumab Ozogamicin Plus Dose-Adjusted EPOCH: Promise in R/R B-ALL
Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).
Same Hypertension, Different Levels of Portal Engagement, Disparities Research Shows
When patients are treated in primary care for high blood pressure, sociodemographic factors sway the rates at which they access patient portals, investigators found. This could influence their hypertension outcomes.
TB Vaccine Shows Protection Against COVID-19 in People With T1D
In the course of investigating the use of Bacillus Calmette-Guérin for high-risk individuals who have type 1 diabetes (T1D), researchers hoped—and found—that BCG could substantially reduce the chance of those with T1D contracting COVID-19; BCG has historically been used to prevent tuberculosis (TB).
Ponatinib, Imatinib Face Off, but Still Room for TKI Improvement in Ph+ ALL
Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), but questions linger about ponatinib’s long-term safety.
Unique Case: HCC With No Cirrhosis—and “Hidden” CLL/SLL
A 77-year-old man had no risk factors for hepatocellular carcinoma (HCC), but he was nonetheless found to have it. Along the way, he was also diagnosed with previously undetected chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).